002294:SZSEShenzhen Salubris Pharmaceuticals Co., Ltd. Class A Analysis

Shenzhen Salubris Pharma is trading at CNY 30.38, well below its 20‑day SMA of 32.26 and far under the 50‑day (43.71) and 200‑day (52.28) averages, indicating a strong bearish bias. However, the RSI of 23 signals deep oversold conditions and the MACD histogram has turned positive, suggesting a potential short‑term rebound toward the nearest resistance at CNY 36.5. The stock’s volatility is high at roughly 50% over the past 30 days, yet its beta is only 0.06, implying limited correlation with broader market moves. Fundamentally, revenue grew 15.7% YoY with a robust gross margin of 75% and operating cash flow of CNY 1.07 bn, but the PE ratio of 50.6 dwarfs the industry average of 24, and a DCF‑derived fair value of just CNY 3.20 underscores severe overvaluation. The company holds ample cash (CNY 1.83 bn) against modest debt, but free cash flow is thin, and the dividend payout is zero, making dividend sustainability irrelevant.